Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu HL, Rothmann MD, Brar S, Wang J, Garnett C, Bullock J, Burke LB, Rahman A, Sridhara R, Farrell A, Pazdur R. Deisseroth A, et al. Among authors: rothmann md. Clin Cancer Res. 2012 Jun 15;18(12):3212-7. doi: 10.1158/1078-0432.CCR-12-0653. Epub 2012 Apr 27. Clin Cancer Res. 2012. PMID: 22544377
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R. Giusti RM, et al. Clin Cancer Res. 2008 Mar 1;14(5):1296-302. doi: 10.1158/1078-0432.CCR-07-1354. Clin Cancer Res. 2008. PMID: 18316547 Clinical Trial.
Missing data in biologic oncology products.
Rothmann MD, Koti K, Lee KY, Lu HL, Shen YL. Rothmann MD, et al. J Biopharm Stat. 2009 Nov;19(6):1074-84. doi: 10.1080/10543400903242993. J Biopharm Stat. 2009. PMID: 20183465
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R. Lemery SJ, et al. Among authors: rothmann md. Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2. Clin Cancer Res. 2010. PMID: 20601446
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Casak SJ, Lemery SJ, Shen YL, Rothmann MD, Khandelwal A, Zhao H, Davis G, Jarral V, Keegan P, Pazdur R. Casak SJ, et al. Among authors: rothmann md. Oncologist. 2011;16(1):97-104. doi: 10.1634/theoncologist.2010-0306. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212432 Free PMC article. Review.
32 results